More on KYNB
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $6.99 |
|
|||
| Open | $6.93 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $7.11 | ||||
| Day Low | $6.93 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,381 | ||||
- Kyntra Bio to Report Second Quarter 2026 Financial Results
- Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35
- Kyntra Bio presents roxadustat data showing transfusion improvements in MDS
- Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
- Rodman & Renshaw Starts Kyntra Bio (KYNB) at Buy
- Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
- Kyntra Bio to Report First Quarter 2026 Financial Results
- RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation
- Kyntra Bio receives Nasdaq delisting notice for asset requirement
- Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
Entities mentioned with KYNB
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Twitter | View Related Stories »
- Rodman & Renshaw | View Related Stories »
- Needham & Company | View Related Stories »
- Show More...
